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Abstract: Crohn’s disease is a chronic inﬂ  ammatory disease that can affect any part of the 
gastrointestinal tract. Classically the disease has a predilection for the distal small bowel and 
colon and presents with dominant symptoms of abdominal pain and diarrhea. This case report 
describes a 38-year-old woman with Crohn’s disease who presented with odynophagia. Direct 
visualization of the oropharynx revealed a large serpiginous Crohn’s disease ulcer. A precipi-
tous drop in hemoglobin prompted a series of gastroenterologic investigations that conﬁ  rmed 
both ileal and oropharyngeal Crohn’s disease. This manuscript describes the presentation of 
oropharyngeal Crohn’s and reviews previous reports and management options.
Keywords: Crohn’s disease, odynophagia, immunomodulatory therapy, oropharyngeal Crohn’s 
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Introduction
Crohn’s disease involves chronic inﬂ  ammation of the mucosal tissues that may advance 
to ﬁ  ssuring ulcers, sinus tracts, submucosal ﬁ  brosis, transmural lymphoid inﬁ  ltrates 
and serositis, affecting any part of the alimentary tract.1,2 The etiology of Crohn’s dis-
ease remains to be elucidated, however, it likely occurs as a consequence of luminal 
antigens [microbial and/or dietary] triggering an uncontrolled mucosal and systemic 
inﬂ  ammatory response in a genetically predisposed individual.3,4 While the peak age 
of onset is between 15 and 25 years of age, individuals can be of any age at the time of 
disease onset. Typical symptom presentation includes abdominal cramping, diarrhea, 
weight loss, and anemia. The diagnosis of Crohn’s disease requires a combination of 
endoscopic and histological evaluations to differentiate it from other forms of chronic 
gastrointestinal inﬂ  ammation.2
Crohn’s disease is most common in the distal small bowel and colon. At the time 
of presentation, 80% of patients have small bowel disease (predominantly distal 
ileum), 50% have ileocolitis, and only 20% have disease limited to the large bowel.5 
Rarely does Crohn’s disease present with symptoms localized to the oropharynx or 
upper-gastrointestinal tract.5
Case presentation
A 38-year-old female presented to her family doctor with a 2-week history of throat 
pain, odynophagia, and an associated 5.4 kg weight loss. She noted a history of fre-
quent oral “canker sores”. Throat swabs were negative for infectious etiologies and 
there was no improvement with two separate courses of antimicrobials. There were no 
genital ulcers or eye symptoms noted by the patient and none on examination. When 
the throat pain and odynophagia progressed to the point of signiﬁ  cantly limiting oral 
intake the woman was admitted to the otolaryngology specialty service for further 
investigation and treatment. Direct visualization of the oral pharynx revealed a large 
2 cm, serpiginous ulcerating lesion proximal to the pyriform fossae. Given the fact 
that the patient was a one pack per day smoker, the diagnosis of a primary malignant 
lesion was entertained.Clinical and Experimental Gastroenterology 2008:1 16
Mohamed et al
Before a biopsy of the lesion could be arranged a drop in 
the patient’s hemoglobin from 112 g/L to 65 g/L occurred 
over a 36-hour interval. The patient noted some increase in 
bowel frequency and bright red blood mixed with the feces. 
Consultation to the Gastroenterology Service was initiated 
and a esophago-gastro-duodenoscopy revealed a normal 
esophagus, stomach, and proximal duodenum with no obvi-
ous upper gastrointestinal source to account for the anemia. 
Colonoscopy demonstrated a normal peri-anal region, rec-
tum, and colon; however, on intubation into the terminal 
ileum, there were several long, discrete deep ulcers and 
exudate (Figure 1). Histologic analysis conﬁ  rmed Crohn’s 
disease. With this ﬁ  nding of Crohn’s disease in the terminal 
ileum the esophago-gastro-duodenoscopy was repeated with 
the aim of carefully inspecting the oropharynx for evidence or 
oropharyngeal Crohn’s disease. A large (2 × 2 cm), irregular, 
non-bleeding ulcer was seen in the oropharynx, consistent 
in size and location with the one identiﬁ  ed during direct 
visualization (Figures 1 and 2). Histologic analysis of the 
oropharyngeal ulcer conﬁ  rmed Crohn’s disease. On retro-
spective questioning the patient recalled a 3-year history of 
intermittent diarrhea (5–6 bowel movements per day) with 
intermittent blood in the stool, and associated abdominal 
cramping and occasional vomiting. The patient’s mother 
had a history of ulcerative colitis. There was no other family 
history of inﬂ  ammatory bowel disease.
Following the patient’s endoscopic examinations and 
diagnosis of Crohn’s disease, treatment was initiated with 
methylprednisolone 40 mg intravenously every 12 hours and 
azathioprine 150 mg po daily. Following 3 days of intrave-
nous steroid treatment the patient had signiﬁ  cantly improved, 
noting cessation of her diarrhea and rectal bleeding as well 
as marked improvement of her throat pain and odynophagia. 
After 5 days the patient was ingesting a regular diet and the 
intravenous steroid treatment was changed to oral prednisone. 
The woman was discharged home on a tapering dose of pred-
nisone (initially 40 mg daily, and tapering over 16 weeks to 
zero) and azathioprine 150 mg daily.
The patient remained in clinical remission on mainte-
nance azathioprine 150 mg per day for 8 months at which 
point she began having recurrence of throat pain and odyno-
phagia. Symptoms of abdominal pain and diarrhea were not 
a feature of the relapse. Endoscopic examination revealed 
recurrence of the oropharyngeal ulceration. Infliximab, 
5 mg/kg, was initiated at week 0 and 2. Within 6 days after 
the ﬁ  st infusion there was almost complete resolution of the 
oral symptoms. Inﬂ  iximab every 8 weeks as scheduled 
therapy and azathioprine 150 mg per day were continued as 
maintenance therapy.
Discussion
The ﬁ  rst case report of oropharyngeal Crohn’s disease was 
described in 1969 (6). Since then, it is estimated that only 
0.5% to 20% of Crohn’s disease patients will have some 
oropharyngeal involvement of Crohn’s disease with perhaps 
a higher incidence in children.7,8 Oral ﬁ  ndings in Crohn’s 
disease are most commonly intermittent shallow aphthous 
ulcers, but much less commonly include mucogingivitis, 
mucosal tags, lip swelling, and pyostomatitis vegetans (ulcer-
ation with mucosal and gingival pustules). Large oropharyn-
geal ulcers, as seen in this case, are rarely described.8 The 
differential diagnosis of oropharyngeal ulceration extends 
beyond inﬂ  ammatory bowel diseases to include infectious 
(tuberculosis, toxoplasmosis, syphilis), inﬁ  ltrative (sarcoid), 
inﬂ  ammatory (Behçet’s), caustic, and neoplastic (lymphoma, 
squamous cell carcinoma) etiologies.9
The partiality of Crohn’s disease for one region of the 
gastrointestinal tract versus another is not completely under-
stood. Compromised oral mucosal integrity secondary to 
reduced circulating salivary IgA levels has been postulated 
as a pathogenic mechanism in oral Crohn’s disease.1 Another 
separate hypothesis involves a hypersensitive cellular and/or 
humoral immune response to oral antigens in Crohn’s patients 
with altered immune regulation.9
Proximal and oropharyngeal gastrointestinal tract Crohn’s 
disease is difﬁ  cult to diagnose and carries its own prognostic 
and treatment implications. Thorough history-taking, direct 
visualization, and tissue biopsy are all important steps in 
establishing the diagnosis.1 In this regard, a systematic evalu-
ation of the mouth by physicians or dentists is an important 
Figure 1 Endoscopic view of the terminal ileum with evidence of large deep 
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step in the diagnostic process.7 Gastroscopy by experienced 
gastroenterologists will identify oropharyngeal Crohn’s 
disease in only 50% of patients.8 This low identiﬁ  cation rate 
is attributed to the limited examination of the oro-and hypo-
pharynx by endoscopists during intubation of the esophagus. 
Indeed, the initial gastroscopy performed in this patient did 
not identify the oropharyngeal ulcer. Only after the colonos-
copy had identiﬁ  ed terminal ileal Crohn’s disease did a repeat 
gastroscopy and careful visualization of the oropharyngeal 
region conﬁ  rm the Crohn’s oropharyngeal ulcer.
Conﬂ  icting data exists on the frequency of granulomas 
seen on biopsy in oral Crohn’s disease lesions. Ramzan et al 
found the proportion of oral lesions attributable to Crohn’s 
disease having granulomas on biopsy to be less than 10%.10 
Conversely, Ganesh et al found 75% of patients in their 
sample to have granulomas.7 There were no granulomas in 
the biopsies obtained from this patient.
Successful treatment of oropharyngeal Crohn’s disease 
has been achieved, in isolated case studies by laser therapy 
and nutrition, however, pharmacologic therapy remains the 
mainstay. It is estimated that less than 25% of oropharyn-
geal Crohn’s disease resolve spontaneously.11 In a single 
case report, laser therapy achieved a successful outcome in 
treating an isolated oral Crohn’s lesion.12 A variety of phar-
macologic agents have been investigated for the treatment 
of oral Crohn’s disease and remain the mainstay of therapy. 
Turchi et al illustrated the success of corticosteroid induced 
remission followed by mesalamine maintenance therapy 
with no relapse after 6 months.1 Inﬂ  iximab is a chimeric 
monoclonal antibody against tissue necrosis factor alpha 
(TNF-alpha) that has an established role in the initiation13 
and maintenance14 of remission in moderate to severe ﬁ  stu-
lizing and non-ﬁ  stulizing Crohn’s disease.15,16 Oral Crohn’s 
lesions resistant to mesalamine and corticosteroid therapy 
have been described to respond to inﬂ  iximab therapy with 
signiﬁ  cant symptom improvement seen with the initial infu-
sion.11,17 Thalidomide is an oral immunomodulatory and anti-
angiogenic medication that has been shown to completely 
resolve oral granulomatous lesions, including oral Crohn’s 
disease in cases refractory to other immunomodulatory 
agents such as azathioprine.18 However, the high incidence 
of dose-dependent and dose-independent adverse effects has 
limited its use.
In summary, oropharyngeal Crohn’s disease presents a 
diagnostic and therapeutic challenge to clinicians. The lesions 
of oropharyngeal Crohn’s disease are frequently missed at the 
time of endoscopy, resulting in delay of diagnosis, and the 
associated odynophagia often leads to limited oral intake and 
subsequent weight loss. Indirect laryngoscopy can provide 
initial identiﬁ  cation of the oral ulcerations, and in the absence 
of neoplasia on biopsy, a careful search for luminal Crohn’s 
disease should be undertaken. The oropharyngeal Crohn’s 
disease in this patient had an initial response to corticoste-
roids and azathioprine, however the response could not be 
maintained despite azathioprine therapy. Inﬂ  iximab therapy 
rapidly induced and maintained a second response.
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